Today the UK Academy of Medical Sciences announced the election of 50 new biomedical health scientists to its influential fellowship; among them Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer. The Academy of Medical Sciences fellowship recognises exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society. The election follows a rigorous nomination process and a peer-reviewed selection by existing Fellows. This year there were 384 nominations, with the Academy selecting 50 diverse and influential scientists as 2021 Fellows. Professor Uchegbu’s major achievement is in recognition of research aimed at understanding drug transport into the brain using nanotechnology. Professor Ijeoma F. Uchegbu says, “I am absolutely honoured to be recognised by my peers and will treasure this mark of esteem, understanding that this honour also belongs to my collaborators and all the scientists who have worked hard in our laboratories.”
About Academy of Medical Sciences
The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Elected Fellows are the UK’s leading medical scientists from hospitals, academia, industry and the public service. The Academy's mission is to advance biomedical and health research and its translation into benefits for society. The Academy is working to secure a future in which:
• UK and global health is improved by the best research. • The UK leads the world in biomedical and health research, and is renowned for the quality of its research outputs, talent and collaborations. • Independent, high quality medical science advice informs the decisions that affect society. • More people have a say in the future of health and research. The Academy of Medical Sciences’ work focusses on four key objectives: promoting excellence, developing talented researchers, influencing research and policy and engaging patients, the public and professionals.
Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was spun out of University College London, a top 10 global university and was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics’ proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated pharmaceutical assets, underpinned by high quality science. For example, the company’s Molecular Envelope (MET) is composed of biocompatible polymers tailored to form containers that package the drug and carry it across epithelial barriers to the target site. This delivers a step change in target tissue availability of drugs and some peptides across a number of epithelial barriers. The founding scientists Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Envelta and MMS019 are one of a number of pre-clinical assets that have been out-licensed by Nanomerics. For more information please visit www.nanomerics.com